Partner With Us NRI

USFDA Approves second Biosimilar Insulin Product

News: USFDA has approved second biosimilar insulin product, Eli Lilly’s Rezvoglar which is a biosimilar to Lantus (insulin glargine) for the US market.

Views: This second Glargine biosimilar in the US is slightly negative for Biocon as this is also with interchangeability clause. Although we believe that Biocon has exclusivity in its biosimilar, this could intensify future competition in Glargine.

Impact: Negative.